



Patient Information	Specimen Information	Client Information
<b>017C3, AH</b>  <b>DOB: 02/20/2021    AGE: 9M</b> Gender: M Phone: NG Patient ID: 017C3	Specimen: WC187368C Requisition: 0000112  Collected: 12/16/2021 Received: 12/17/2021 / 05:39 EST Reported: 12/17/2021 / 20:40 EST	Client #: 11118385    CA000159 JOSLIN LESSARD RSCH Attn: SARAH LESSARD 1 JOSLIN PL BOSTON, MA 02215-5306

Test Name	In Range	Out Of Range	Reference Range	Lab
LIPID PANEL, STANDARD				
<b>CHOLESTEROL, TOTAL</b>		<b>184 H</b>	<170 mg/dL	NL1
HDL CHOLESTEROL	51		>45 mg/dL	NL1
<b>TRIGLYCERIDES</b>		<b>131 H</b>	<75 mg/dL	NL1
LDL-CHOLESTEROL	108		<110 mg/dL (calc)	NL1

LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.

Martin SS et al. JAMA. 2013;310(19): 2061-2068  
(<http://education.QuestDiagnostics.com/faq/FAQ164>)

CHOL/HDL-C RATIO	3.6		<5.0 (calc)	NL1
<b>NON HDL CHOLESTEROL</b>		<b>133 H</b>	<120 mg/dL (calc)	NL1

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

<b>GLUCOSE</b>		<b>102 H</b>	65-99 mg/dL	NL1
----------------	--	--------------	-------------	-----

Fasting reference interval

For someone without known diabetes, a glucose value between 100 and 125 mg/dL is consistent with prediabetes and should be confirmed with a follow-up test.

<b>C-REACTIVE PROTEIN</b>		<b>14.1 H</b>	<8.0 mg/L	NL1
<b>INSULIN</b>		<b>114.8 H</b>	uIU/mL	NL1
	Reference Range	< or = 19.6		

Risk:  
Optimal < or = 19.6  
Moderate NA  
High >19.6

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Quest Diagnostics population data from 12/2011.

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).

# PERFORMING SITE:

NL1 QUEST DIAGNOSTICS LLC, 200 FOREST STREET 3RD FLOOR,SUITE B, MARLBOROUGH, MA 01752-3023 Laboratory Director: SALIM E KABAWAT,MD, CLIA: 22D0076229

# LIST OF RESULTS PRINTED IN THE OUT OF RANGE COLUMN:

<b>CHOLESTEROL, TOTAL</b>	<b>184 H</b>	<170 mg/dL	NL1
<b>TRIGLYCERIDES</b>	<b>131 H</b>	<75 mg/dL	NL1
<b>NON HDL CHOLESTEROL</b>	<b>133 H</b>	<120 mg/dL (calc)	NL1

For patients with diabetes plus 1 major ASCVD risk



Patient Information	Specimen Information	Client Information
<b>017C3, AH</b>  <b>DOB: 02/20/2021    AGE: 9M</b> Gender: M Patient ID: 017C3	Specimen: WC187368C Collected: 12/16/2021 Received: 12/17/2021 / 05:39 EST Reported: 12/17/2021 / 20:40 EST	Client #: 11118385

**LIST OF RESULTS PRINTED IN THE OUT OF RANGE COLUMN:**

factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

<b>GLUCOSE</b>	<b>102 H</b>	65-99 mg/dL	NL1
Fasting reference interval			

For someone without known diabetes, a glucose value between 100 and 125 mg/dL is consistent with prediabetes and should be confirmed with a follow-up test.

<b>C-REACTIVE PROTEIN</b>	<b>14.1 H</b>	<8.0 mg/L	NL1
<b>INSULIN</b>	<b>114.8 H</b>	uIU/mL	NL1
Reference Range < or = 19.6			

Risk:  
Optimal < or = 19.6  
Moderate NA  
High >19.6

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Quest Diagnostics population data from 12/2011.

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).